Covestor’s Pacific Biosciences PACB Stock Holding History

Covestor’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Hold	43	–	–	﹤0.01%	2641
2025 Q4	$0	Sell	43 -1	-2%	-$2	﹤0.01%	2615
2025 Q3	$0	Hold	44	–	–	﹤0.01%	2631
2025 Q2	$0	Sell	44 -3	-6%	-$3	﹤0.01%	2605
2025 Q1	$0	Hold	47	–	–	﹤0.01%	2590
2024 Q4	$0	Sell	47 -16	-25%	-$31	﹤0.01%	2596
2024 Q3	$0	Sell	63 -3	-5%	-$5	﹤0.01%	2600
2024 Q2	$0	Buy	66 +41	+164%	+$83	﹤0.01%	2610
2024 Q1	$0	Buy	25 +11	+79%	+$64	﹤0.01%	2597
2023 Q4	$0	Sell	14 -1	-7%	-$8	﹤0.01%	2553
2023 Q3	$0	Sell	15 -7	-32%	-$80	﹤0.01%	2541
2023 Q2	$0	Hold	22	–	–	﹤0.01%	2499
2023 Q1	$0	Hold	22	–	–	﹤0.01%	2423
2022 Q4	$0	Sell	22 -2	-8%	-$17	﹤0.01%	2451
2022 Q3	$0	Sell	24 -4	-14%	-$23	﹤0.01%	2415
2022 Q2	$0	Sell	28 -8	-22%	-$49	﹤0.01%	2228
2022 Q1	$0	Sell	36 -198	-85%	-$2.28K	﹤0.01%	2340
2021 Q4	$5K	Buy	+234	New	+$5.65K	0.01%	1329

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Covestor's PACB Position: Q1 2026 in Review

Covestor held its Pacific Biosciences (PACB) position steady in Q1 2026 at 43 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2641.

Covestor first reported a position in PACB in Q4 2021 and has held it in 18 quarters since. The position peaked at $5K in Q4 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Covestor held 43 shares of Pacific Biosciences worth $0 as of Q1 2026.
Covestor left its Pacific Biosciences share count unchanged in Q1 2026.
Pacific Biosciences made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2641 holding.
Covestor first reported a position in Pacific Biosciences in Q4 2021 and has held it in 18 quarters since.
Covestor's Pacific Biosciences position peaked at $5K in Q4 2021.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.